Jubilant Pharmova Ltd (JUBLPHARMA)
₹965.35
Mkt cap
₹15,378 Cr
P/E ratio
35.20
P/B
2.17
Div yield
0.52%
ROE
6.55%
ROCE
8.99%
EPS (TTM)
₹27.42
Book value
₹445
52W range
808–1,236
Sector
Healthcare
Jubilant Pharmova Ltd is an integrated global pharmaceuticals company having three business segments i.e. pharmaceuticals, contract research and development services and proprietary novel drugs. [1]
Health check
Cautious
ValuationFair
ProfitabilityWeak
GrowthLow
TechnicalsBearish
52-week range
−21.92% from high₹965
₹808+19.53% from low₹1,236
Current
₹965.35
Prev close
₹969.00
Day
−0.38%
Price performance
1D
−0.38%
1W
−5.71%
1M
+0.10%
3M
+2.11%
6M
+1.53%
1Y
−19.61%
YTD
−8.53%
Financials
FRevenue, profit & margin
P/E ratio
35.2×
JUBLPHARMA is 3% above the sector median of 34.0×
JUBLPHARMA35.2×
Sector median34.0×
| Mar 2023 | Jun 2023 | Sep 2023 | Dec 2023 | Mar 2024 | Jun 2024 | Sep 2024 | Dec 2024 | Mar 2025 | Jun 2025 | Sep 2025 | Dec 2025 | Mar 2026 | Trend | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Sales | 1,678 | 1,587 | 1,680 | 1,677 | 1,759 | 1,732 | 1,752 | 1,822 | 1,929 | 1,901 | 1,966 | 2,122 | 2,290 | |
| Expenses | 1,459 | 1,419 | 1,438 | 1,459 | 1,487 | 1,480 | 1,463 | 1,535 | 1,584 | 1,611 | 1,625 | 1,833 | 1,951 | |
| Operating Profit | 219 | 168 | 242 | 218 | 271 | 252 | 289 | 287 | 345 | 290 | 341 | 289 | 339 | |
| OPM % | 13% | 11% | 14% | 13% | 15% | 15% | 17% | 16% | 18% | 15% | 17% | 14% | 15% | |
| Other Income | 21 | 9 | 19 | 49 | -151 | 410 | 8 | -10 | 9 | 12 | 4 | -19 | 10 | |
| Interest | 56 | 62 | 66 | 71 | 73 | 71 | 61 | 56 | 53 | 49 | 50 | 56 | 56 | |
| Depreciation | 271 | 90 | 97 | 95 | 101 | 91 | 91 | 91 | 95 | 98 | 105 | 121 | 117 | |
| Profit before tax | -86 | 25 | 98 | 101 | -54 | 500 | 144 | 130 | 206 | 154 | 190 | 93 | 176 | |
| Tax % | 16% | 76% | 37% | 34% | 15% | 4% | 29% | 23% | 27% | 34% | 37% | 40% | 32% | |
| Net Profit | -100 | 6 | 62 | 66 | -62 | 482 | 102 | 101 | 151 | 102 | 120 | 56 | 119 | |
| EPS in Rs | -6.15 | 0.40 | 3.92 | 4.19 | -3.68 | 30.26 | 6.45 | 6.33 | 9.64 | 6.46 | 7.55 | 3.51 | 7.50 | |
| Raw PDF |
Earnings
EResults dates & reactionsNo upcoming results date on calendar.
Fresh quarters land in the Financials table above, tagged NSE until screener catches up.
Avg earnings-day move −1.21% · closed higher next day 22 of last 61
| Q1FY24 | Q2FY24 | Q3FY24 | Q4FY24 | Q1FY25 | Q2FY25 | Q3FY25 | Q4FY25 | Q1FY26 | Q2FY26 | Q3FY26 | Q4FY26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Broadcast | 20 Jul '23 | 28 Oct '23◦ | 2 Feb '24◦ | 29 Oct '24 | 19 Jul '24◦ | 25 Oct '24◦ | 31 Jan '25◦ | 16 May '25◦ | 29 Jul '25 | 31 Oct '25 | 6 Feb '26 | 22 May '26 |
| Earnings day | −1.73% | −4.05% | −1.79% | +1.10% | −3.37% | +3.60% | +0.37% | +1.53% | −1.81% | −1.56% | −3.72% | −0.52% |
| +1 day | −3.54% | −5.71% | −1.91% | +3.25% | −3.38% | +4.74% | −2.32% | +4.62% | +5.29% | +4.60% | −3.21% | −0.43% |
| +5 days | −5.33% | +0.69% | −1.01% | +13.68% | −3.48% | +16.98% | +2.68% | +18.60% | −4.69% | +1.79% | −6.25% | −2.38% |
| +15 days | +16.48% | +8.12% | −2.68% | +3.84% | +13.59% | +6.80% | −0.72% | +20.97% | −7.67% | −3.75% | −11.04% | −2.01% |
| +30 days | +21.46% | +15.19% | −4.18% | +1.64% | +22.33% | +6.28% | −8.57% | +28.02% | −4.22% | −2.91% | −16.19% | −3.25% |
| Filing | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL | XBRL |
Corporate actions
CLast 6 months| Kind | Value | Ex-date | Record |
|---|---|---|---|
| dividend Dividend - Rs 5 Per Share | 5.00 | 24 Jul '26 | 24 Jul '26 |
Shareholding
Sas of Jun 202647.67%Promoter
Promoters47.67%
FIIs15.87%0.03
DIIs12.40%0.77
Public23.50%0.75
Ownership trend
Peers
P8 companiesValuation vs quality
P/E × ROCE · bubble = market cap| Name | CMP | P/E | Mkt Cap | Div Yld | NP Qtr | Qtr Profit Var | Sales Qtr | Qtr Sales Var | ROCE |
|---|---|---|---|---|---|---|---|---|---|
| Sun Pharma.Inds. | ₹1,941.10 | 37.48 | 4,65,735 | 0.82% | 2,710 | +13.58% | 14,612 | +12.76% | 20.53% |
| Divi's Lab. | ₹7,248.50 | 73.36 | 1,92,425 | 0.41% | 751 | +13.44% | 2,831 | +9.52% | 21.97% |
| Torrent Pharma. | ₹4,961.50 | 86.11 | 1,88,720 | 0.77% | 364 | −20.58% | 4,197 | +41.84% | 15.19% |
| Cipla | ₹1,410.60 | 31.84 | 1,13,955 | 0.92% | 786 | −39.19% | 7,119 | +2.33% | 15.49% |
| Zydus Lifesci. | ₹1,108.70 | 20.38 | 1,10,593 | 0.09% | 1,341 | +21.92% | 7,587 | +16.22% | 21.14% |
| Lupin | ₹2,370.50 | 19.06 | 1,08,387 | 0.76% | 1,469 | +101.49% | 7,475 | +31.89% | 29.93% |
| Mankind Pharma | ₹2,507.20 | 51.44 | 1,03,546 | 0.04% | 559 | +34.23% | 3,443 | +11.81% | 13.53% |
| Jubilant Pharmo | ₹965.35 | 35.20 | 15,378 | 0.52% | 119 | −17.45% | 2,290 | +18.73% | 8.99% |
| Median: 157 Co. | ₹432.05 | 34.03 | 1,978 | 0.10% | 15 | +28.10% | 176 | +17.66% | 15.10% |
Filings
DAnnual reports15
Financial Year 2025bseFinancial Year 2024bseFinancial Year 2023bseFinancial Year 2022bseFinancial Year 2021bseFinancial Year 2020bseFinancial Year 2019bseFinancial Year 2018bseFinancial Year 2017bseFinancial Year 2016bseFinancial Year 2015bseFinancial Year 2014bseFinancial Year 2013bseFinancial Year 2012bseFinancial Year 2011nse
Concall transcripts51
TranscriptMay 2026PPTMay 2026PPTFeb 2026PPTOct 2025TranscriptJul 2025PPTJul 2025PPTMay 2025TranscriptFeb 2025PPTFeb 2025PPTJan 2025PPTOct 2024PPTJul 2024PPTMay 2024PPTMay 2024PPTFeb 2024PPTOct 2023PPTJul 2023PPTMay 2023TranscriptFeb 2023TranscriptNov 2022PPTNov 2022TranscriptAug 2022TranscriptJun 2022PPTMar 2022
Credit ratings6
Announcements5
Announcement under Regulation 30 (LODR)-Newspaper Publication 19 Jul - Newspaper publication - Dispatch of Postal BallotShareholder Meeting / Postal Ballot-Notice of Postal Ballot 18 JulApproval For Grant Of Stock Options/Rsus/Psus 16 Jul - Granted 2,07,003 stock options, RSUs and PSUs on July 16, 2026 under ESOP 2018.Rectification OrderThe Income Tax Department 16 Jul - Income tax rectification order deletes Rs. 22.10 crore demand for AY 2020-21.Disclosure under Regulation 30A of LODR 16 Jul - Income Tax rectification order deleted Rs. 22.10 crore demand for AY 2020-21 on July 15, 2026.